Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S019 - Controversies and Difficult Questions Concerning Biologic Therapeutics

Saturday, February 17; 9:00 AM - 12:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify the key variables affecting biologics drug choice in psoriasis.
  • Identify major risks from biologics drug therapy for psoriasis.
  • Examine the oral versus biologics drug therapy options for adult atopic dermatitis.


The subject of biologic therapeutics in dermatology is complicated. We will address variables affecting the choice of drug options in patients with psoriasis, adult atopic dermatitis, and hidradenitis suppurativa. These drugs have definable risks, possibly including malignancy induction, which will be carefully analyzed. Given the tremendous costs of these drug options, assessing adequacy of publications for off-label indications is essential. Finally we will address the issue of disparities in access to biologics therapeutics.


  • Gordon, Kenneth B., MD: AbbVie – C(H), I(Grants/Research Funding); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Celgene Corporation – A(H), I(Grants/Research Funding); Demira – C(H); Dermavant Sciences – C(H); Eli Lilly and Company – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – A(H), I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – C(H); Leo Pharma Inc – C(H); Lilly ICOS LLC – A(H); Novartis – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H); Othro Dermatologics – C(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – C(H); UCB – C(H);
  • Heffernan, Michael P., MD: AbbVie – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); Celgene – I(Grants/Research Funding); Dermavant Sciences – I(Grants/Research Funding); DS Laboratories – I(Grants/Research Funding); Eli Lilly and Company – C(H), Speaker/Faculty Education(H); Foamix – I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); LEO Pharma, US – I(Grants/Research Funding); Merck Serono – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding);
  • Kimball, Alexandra Boer, MD, MPH: AbbVie – C(H), I(Grants/Research Funding), I(Residency/Fellowship Program Funding); Almirall – C(H); BMS – C(H); Dermira – C(H); Escalier Biosciences – A(H), A(OB); Janssen Biotech – C(H); Janssen Pharmaceuticals, Inc – I(Residency/Fellowship Program Funding); Lilly ICOS LLC – C(H); Novartis – C(H), I(Grants/Research Funding); Procter & Gamble Company – C(H); Regeneron – C(H); Sanofi/Regeneron – C(H); UCB – C(H); Unilever – A(H);
  • Strober, Bruce Elliot, MD, PhD: AbbVie – A(H), C(H), I(NC), O(NC); Affibody – C(Fees); Almirall – C(H); Amgen – C(H), I(NC); Boehringer Ingelheim – C(H), I(NC); Bristol-Myers Squibb – A(H), C(Fees); Celgene Corporation – A(H), C(H), I(NC); Dermavant Sciences – C(Fees); Dermira – A(H), C(H); Eli Lilly and Company – A(H), C(H), I(NC); Galderma Research & Development, LLC – I(Grants/Research Funding); GlaxoSmithKline – C(H); Janssen-Ortho Inc. – A(H), C(H), I(NC), O(NC); Leo Pharma Inc – C(H); Medac Pharma, Inc – C(H); Meiji Seika Pharma Co., Ltd – C(Fees); Menlo Therapeutics – C(H); Merck & Co., Inc – I(NC); Novartis Pharmaceuticals Corp. – A(H), C(H); Ortho Dermatologics – C(H); Pfizer Inc. – A(H), C(H), I(NC); Sanofi/Regeneron – A(H), C(H); Sun Pharmaceutical Industries Ltd. – A(H), C(H), I(NC); UCB – A(H), C(Fees);
  • Takeshita, Junko, MD, PhD: Pfizer Inc. – I(Grants/Research Funding);
  • Wolverton, Stephen E., MD: Elsevier Inc. – Independent Contractor(OB);
Saturday, February 17
9:00 AM
Dr. Wolverton / Variables affecting biologics drug choice
9:30 AM
Dr. Heffernan / Well documented off-label indications for biologics drug therapy
10:00 AM
Dr. Strober / Malignancy risk from biologics
10:30 AM
Dr. Kimball / Data from multiple biologics for hidradenitis suppurativa
11:00 AM
Dr. Gordon / Biologics versus oral meds for atopic dermatitis
11:30 AM
Dr. Takeshita / Differences and disparities in biologics utilization and access
Event Details
  • Date
    Saturday, February 17
  • Time
    9:00 AM - 12:00 PM
  • Location
    Room 2
  • CME Credits
  • Type
  • Stephen E. Wolverton, MD, FAAD
  • Alexandra Boer Kimball, MD, MPH, FAAD
  • Bruce Elliot Strober, MD, PhD, FAAD
  • Junko Takeshita, MD, PhD, FAAD
  • Kenneth B. Gordon, MD, FAAD
  • Michael P. Heffernan, MD, FAAD - Handout